Camrelizumab plus apatinib in patients with recurrent or metastatic nasopharyngeal carcinoma failing first-line therapy: An open-label, single-arm, phase II study

被引：0
|
作者：
Ding, X. [1 ]
Zhang, W. [2 ]
You, R. [1 ]
Zou, X. [1 ]
Wang, Z. [3 ]
Ouyang, Y-F. [1 ]
Liu, Y-L. [1 ]
Peng, L. [1 ]
You-Ping, L. [1 ]
Duan, C-Y. [4 ]
Yang, Q. [1 ]
Lin, C. [1 ]
Yulong, X. [1 ]
Chen, S-Y. [1 ]
Gu, C-M. [1 ]
Huang, P. Y. [1 ]
Hua, Y. [1 ]
Chen, M. [1 ]
机构：
[1] Sun Yat Sen Univ, Dept Nasopharyngeal Carcinoma, Canc Ctr, Guangzhou, Peoples R China
[2] Sun Yat Sen Univ, Nasopharyngeal Carcinoma, Canc Ctr, Guangzhou, Peoples R China
[3] Kunming Med Univ, Affiliated Hosp 1, Radiotherapy, Kunming, Yunnan, Peoples R China
[4] Southern Med Univ, Sch Publ Hlth, Biostat, Guangzhou, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期
关键词：
D O I：
10.1016/j.annonc.2022.07.787
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
663P
引用
收藏
页码：S846 / S846
页数：1
相关论文
共 50 条
  • [1] Camrelizumab Plus Apatinib in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma: An Open-Label, Single-Arm, Phase II Study
    Ding, Xi
    Zhang, Wei-Jing
    You, Rui
    Zou, Xiong
    Wang, Zhi-Qiang
    Ouyang, Yan-Feng
    Peng, Lan
    Liu, You-Ping
    Duan, Chong-Yang
    Yang, Qi
    Lin, Chao
    Xie, Yu-Long
    Chen, Si-Yuan
    Liu, Yong-Long
    Gu, Chen-Mei
    Xie, Ruo-Qi
    Huang, Pei-Yu
    Hong, Ming-Huang
    Hua, Yi-Jun
    Chen, Ming-Yuan
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (14) : 2571 - +
  • [2] Camrelizumab plus apatinib in patients with recurrent and/or metastatic nasopharyngeal carcinoma: A single-arm, multicenter, phase 2 trail.
    Mo, Yunyan
    Pan, Yufei
    Zhang, Bin
    Zhang, Jian
    Liu, Zhengchun
    Luo, Meiqing
    Su, Yixin
    Jiang, Wei
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E18025 - E18025
  • [3] Apatinib plus camrelizumab in patients with advanced cervical cancer: A multicentre, open-label, single-arm, phase II trial
    Huang, X.
    Shen, J.
    Xiong, Y.
    Wang, Y.
    Cao, X.
    He, M.
    Zou, G.
    Deng, Y.
    Wang, X.
    Lan, C.
    [J]. GYNECOLOGIC ONCOLOGY, 2020, 159 : 43 - 43
  • [4] Camrelizumab Plus Apatinib in Patients With Advanced Cervical Cancer (CLAP): A Multicenter, Open-Label, Single-Arm, Phase II Trial
    Lan, Chunyan
    Shen, Jingxian
    Wang, Yin
    Li, Jundong
    Liu, Zhimin
    He, Mian
    Cao, Xinping
    Ling, Jiayu
    Huang, Jiaming
    Zheng, Min
    Zou, Guorong
    Yan, Haowen
    Liu, Qing
    Yang, Fan
    Wei, Wei
    Deng, Yanhong
    Xiong, Ying
    Huang, Xin
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (34)
  • [5] Camrelizumab plus apatinib in patients with advanced cervical cancer: A multicenter, open-label, single-arm, phase II trial.
    Lan, Chunyan
    Huang, Xin
    Shen, Jing-Xian
    Wang, Yin
    Xiong, Ying
    Li, Jundong
    Cao, Xinping
    Deng, Yanhong
    He, Mian
    Zou, Guorong
    Wang, Xiaodi
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [6] Camrelizumab plus apatinib for previously treated advanced adrenocortical carcinoma: A single-arm, open-label, phase 2 trial
    Wei, Zhigong
    Zhu, Yuchun
    Cai, Lei
    Peng, Xingchen
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [7] Apatinib in patients with recurrent or metastatic thymic epithelial tumor: a single-arm, multicenter, open-label, phase II trial
    Song, Zhengbo
    Lou, Guangyuan
    Wang, Yina
    Yang, Zhiping
    Wang, Wenxian
    Ji, Yongling
    Chen, Shiqing
    Xu, Chunwei
    Hu, Xiao
    Zhang, Yiping
    [J]. BMC MEDICINE, 2022, 20 (01)
  • [8] Apatinib in patients with recurrent or metastatic thymic epithelial tumor: a single-arm, multicenter, open-label, phase II trial
    Zhengbo Song
    Guangyuan Lou
    Yina Wang
    Zhiping Yang
    Wenxian Wang
    Yongling Ji
    Shiqing Chen
    Chunwei Xu
    Xiao Hu
    Yiping Zhang
    [J]. BMC Medicine, 20
  • [9] Camrelizumab in combination with apatinib as second-line treatment for advanced esophageal squamous cell carcinoma: A single-arm, open-label, phase II study
    Wang Feng
    Wang Junsheng
    Wu Tao
    Hong Yonggui
    Meng Xiangrui
    Ren Zhonghai
    Guo Yanzhen
    Yang Xiuli
    Shi Pei
    Yang Jiamei
    Fan Qingxia
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [10] Radiotherapy plus camrelizumab and irinotecan for oligometastatic esophageal squamous cell carcinoma patients after first-line immunotherapy plus chemotherapy failure: An open-label, single-arm, phase II trial
    Zhao, Wensi
    Ke, Shaobo
    Cai, Xiaojun
    Zuo, Zhigang
    Shi, Wei
    Qiu, Hu
    Cai, Gaoke
    Gong, Yi
    Wu, Yong
    Ruan, Shasha
    Chen, Yongshun
    [J]. RADIOTHERAPY AND ONCOLOGY, 2023, 184
12345